河北医学Issue(6)：946-948,949,4.DOI:10.3969/j.issn.1006-6233.2014.06.023
依达拉奉和长春西汀治疗急性脑梗死的药物经济学评价
Pharmaco-economic Evaluation on Edaravone and Vinpocetine in Treatment of Acute Cerebral Infarction
毛玉芳1
作者信息
- 1. 四川省资阳市第二人民医院药剂科，四川 资阳 641400
- 折叠
摘要
Abstract
Objective:To analyze the cost-effectiveness of edaravone and vinpocetine in treatment of a-cute cerebral infarction by pharmaco-economic principles and to provide foundation for clinical rational use of drug .Method:80 eligible patients were selected and randomly divided into group A and group B , 40 pa-tients in each group;The patients in group A was treated with edaravone , while those in group B treated with vinpocetine , and the conventional therapy protocols for the two groups were the same;at the end of course of treatment, the therapeutic effects were evaluated and the cost-effectiveness analyzed .Result: The total ef-fective rate of group A was 97.50%, which was higher than that of group B (90.00%), but the difference was statistically insignificant (P>0.05).The cost-effectiveness ratio (C/E) of group A was 2.65, which sig-nificantly higher than that of group B (1.74), and the incremental cost-effectiveness ratio (ΔC/ΔE) was 111.34;as for sensitivity analysis, C//E of group A was 2.39, significantly higher than that of group B (1. 58), and ΔC//ΔE was 112.99.Conclusion: Edaravone and vinpocetine in treatment of acute cerebral in-farction can both obtain good therapeutic effects , and vinpocetine has higher pharmaco-economic values .关键词
急性脑梗死/依达拉奉/长春西汀/成本-效果分析Key words
Acute cerebral infarction/Edaravone/Vinpocetine/Cost-effectiveness analysis引用本文复制引用
毛玉芳..依达拉奉和长春西汀治疗急性脑梗死的药物经济学评价[J].河北医学,2014,(6):946-948,949,4.
